Adverum Biotechnologies Inc (FRA:AVU0)
€ 5.45 -0.05 (-0.91%) Market Cap: 116.09 Mil Enterprise Value: 40.31 Mil PE Ratio: 0 PB Ratio: 0.85 GF Score: 31/100

Adverum Biotechnologies Inc Key Opinion Leader Discussion of Additional Cohort 1 Data from the Phase 1 OPTIC Trial Transcript

Oct 12, 2019 / 05:30PM GMT
Leone D. Patterson
Adverum Biotechnologies, Inc. - CEO & Director

So it's webcast today. So just need to make sure we're right on the time with 10:30 time slot.

Okay. Good morning, and welcome, everyone, to the Adverum KOL event. I'm Leone Patterson, the CEO of Adverum. And I know there's a lot going on AAO today, so I'm glad you could all make it here. I think we will make it interesting enough to -- with the specialists we have today that are going to be on our panel along with the additional data that we have presented yesterday that we would love to take you through.

We have about an hour, so I'll keep my opening remarks short and -- because we want to allow time for obviously our retinal specialists to provide their outlook on treating patients of wet AMD and also allow enough time for Q&A.

A copy of our slides can be found on our website at adverum.com. And also we will be making forward-looking statements today, which will be subject to risks and also uncertainties that may cause actual results to differ.

So starting with the agenda, which we think is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot